JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Neoadjuvant therapy for Rectal cancer
IN THE NAME OF GOD. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy The American Journal.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
Rectal Cancer: A Complete Clinical Response…Now what?
Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Colorectal Cancer An oncologists perspective
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
Dept Surgery, Colorectal unit University Hospital, Uppsala, Sweden
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Chemoradiotherapy for Rectal cancer Dr. A. Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of.
Brendan Moran Basingstoke OCTOBER 2008
Role of EUS in colon lesions Pietro Fusaroli Gastroenterologia Università di Bologna.
Specialist surgery “Some surgeons perform less than optimal surgery. Some are less competent technically than their colleagues; and some fail to supervise.
Radiotherapy for Colo-rectal Cancer. Case 1 בן 58 גידול בגובה 9 ס"ם מפי הטבעת קולונוסקופיה – גידול צירקולרי, כמעט חוסם TRUS T3 N0 מועמד לניתוח TME טיפול??
What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.
1 Recent trends in colorectal cancer in Norway: incidence, management and outcomes Arne Wibe, MD, PhD Professor of Surgery St. Olavs Hospital Trondheim,
Adductor Compartment STS - Does method of treatment affect outcome? Anup Pradhan, Yiu-Chung Cheung Birmingham Medical School, UK Supervisors: Mr Robert.
CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.
TME trial TME radiotherapy 5 x 5 Gy TME alone randomisation n = 1861 resectable rectal carcinoma if CRM+: 50 GY.
Transanal Endoscopic Operation Indication – Technique – Results M. Sailer Department of Surgery Bethesda Hospital – Hamburg, Germany.
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.
Rectal Cancer: French Prodige Study: Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.
RT with TME surgery ? OUTLINEOUTLINE. Prostate Seminal vessels Neurovascular bundle Denonvilliers Fascia “holy plane” (Fascia rectalis) Total Mesorectal.
Pathologist and Prognosis in Colorectal Cancer Surgery. Dr Bryan F Warren Consultant Gastrointestinal Pathologist Oxford M62 Course 2004.
Accuracy of EUS in diagnosis of rectal cancer KKUH experience
AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012.
Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
RADIOTHERAPYin VULVAR CANCER 2013 ANZGOG Kailash Narayan.
Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”
Basingstoke Colorectal The Particular Problem of Low Rectal Cancer Brendan Moran Basingstoke 4 th East-West Colorectal Days Hungary 2008.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
Role of MRI in Primary Rectal Cancer Staging and Management
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Rectal cancer staging go the full “DISTANCE” Geertje Noë.
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Multidisciplinary treatment of rectal cancer. Medical oncology Carlo Aschele E.O. Ospedali Galliera – Genova - Italy Carlo Aschele E.O. Ospedali Galliera.
Rectal Cancer MOTP Half Day September 9, 2008
RECTAL CARCINOMA AND PREOPERATIVE MRI: USING A NATIONAL DATASET FOR REGIONAL AUDIT South West Cancer Intelligence Service J Weeks
종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Laparoscopic surgery for rectal cancer What is the evidence?
Karcinom rektuma- management
Non-operative Management of Rectal Cancer
Gastrointestinal Cancer
AUTHORS: DR VERNA VANDERPUYE,: DR JOEL YARNEY,: FRANCIS ASAMOAH:
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Neoadjuvant therapy of rectal cancer – how can we make it better?
Dr Jessica Jenkins Consultant Oncologist
Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.
The STAR-TREC Trial SIV Presentation
Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes - 
 Bruce Minsky.
Developments in Colorectal Cancer
Presentation transcript:

JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital

Neoadjuvant Therapy for Rectal Cancer Background Benefits of neoadjuvant therapy Selection Criteria Staging & CRM Multidisciplinary Team (MDT) approach

Background During the 1990s, TME and postoperative adjuvant chemoradiotherapy (CRT) for locally advanced rectal tumors was the gold standard treatment regimen High Local recurrence (LR) rates despite the use of adjuvant CRT investigators decided to test neoadjuvant radiotherapy (RT) or CRT investigators decided to test neoadjuvant radiotherapy (RT) or CRT

Short course pre-op RT Local recurrence Survival Swedish (1997) rectal cancer trial (pre-TME) 27% to 11% (p<0.001) 5-yr survival 48% to 58% (p=0.004) Dutch TME trial (2001) 8.2% to 2.4% (p<0.001) No difference

Pre-op radiotherapy Swedish rectal cancer trial (1997) Pre TME era, n=1168 Pre TME era, n=1168 Short course pre-op RT Short course pre-op RT Significant reduction of local recurrence from 27% to 11% (p<0.001), and in all Dukes stage Significant reduction of local recurrence from 27% to 11% (p<0.001), and in all Dukes stage Improved 5-year survival from 48% to 58% (p=0.004) Improved 5-year survival from 48% to 58% (p=0.004) Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336: 980–7.

Pre-op radiotherapy Dutch colorectal cancer group (2001) TME trial Post TME era, n=1805 Post TME era, n=1805 Short course pre-op RT Short course pre-op RT Significant reduction of local recurrence from 8.2% to 2.4% (p<0.001) Significant reduction of local recurrence from 8.2% to 2.4% (p<0.001) No difference in overall survival No difference in overall survival Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638–46.

Pre-op radiotherapy UK Medical Research Council (MRC CR07) & National Cancer Institute of Canada trial (NCIC-CTG C016) Local recurrence at 3 years Local recurrence at 3 years Pre-op short course RT: 4.4% Selective Post-op adjuvant chemoRT: 10.6% Relative risk reduction 61% (p<0.0001) No difference in overall survival No difference in overall survival Sebag-Montefiore D et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet Mar 7;373(9666):

Short course preop RT on local recurrence Relative risk reduction in LR 57%

Neoadjuvant RT Vs Neoadjuvant ChemoRT Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD DOI: / CD pub2 Chemotherapy in addition to neoadjuvant RT improves complete response

German rectal cancer study group Neoadjuvant CRT Vs Adjuvant CRT Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731– 40. Overall SurvivalLocal Recurrence

Neoadjuvant CRT has less toxicities Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731– 40.

Neoadjuvant ChemoRT is recommended for locally advanced rectal cancer Local recurrence for locally advanced CA rectum TME only TME + adjuvant chemoRT Neoadjuvant RT + TME Neoadjuvant chemoRT + TME Reduction in local recurrence

Advantages of neoadjuvant CRT apply to virgin, well-oxygenated tissue more profound reduction of local recurrence compared with postoperative CRT more profound reduction of local recurrence compared with postoperative CRT downstage the tumor downstage the tumor make radical resection or sphincter preserving surgery feasible make radical resection or sphincter preserving surgery feasible

Selection Criteria -T 3-4 -N +ve -Predicted CRM ≤ 2mm Accurate pre-op staging is important for neoadjuvant therapy consideration Accurate pre-op staging is important for neoadjuvant therapy consideration

Meta-analysis on T and N staging No accurate investigation for LN EUS is operator dependent, cannot pass stenotic tumor, and can only detect mesorectal lymph nodes Bipat et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology 2004 Sep;232(3): T N

CRM (circumferential resection margin) the distance from the edge of the tumor to the margin of the resected specimen a credible surrogate marker for local recurrence (LR) The prognostic value of CRM involvement is independent of TNM classification. CRM ≤ 2mm consider margin positive

MRI for CRM MRI recommended for CRM assessment MERCURY (Magnetic resonance imaging and rectal cancer european equivalence) study group MRI and histopathologic assessments of tumor spread equivalent to within 0.5 mm MRI and histopathologic assessments of tumor spread equivalent to within 0.5 mm Accurate measurement of the depth of extramural tumor spread Accurate measurement of the depth of extramural tumor spread Mercury Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology Apr;243(1):132-9.

Multidisciplinary Team Multidisciplinary Team Surgeons Pathologists Radiologists Oncologists

Multidisciplinary team (MDT) Discussion at the MDT meeting Increases the proportion of patients receiving neoadjuvant treatment Increases the proportion of patients receiving neoadjuvant treatment Improves local cancer control Improves local cancer control Improves 5-year survival Improves 5-year survival Palmer G et al. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis Oct 19 ePub

Radiologists: Standardized MRI reporting by specialist gasterointestinal radiologists

Oncologists Long Vs Short Scheme CRT Short scheme Long scheme Intensity 5 fractions of 500 cGy 4,500 to 5,060 cGy daily during 4 weeks Time before OT 3-4 days 4-6 weeks Aim Reduce local recurrence Downstage tumour and secure threatened CRM

Chemotherapy Addition of chemotherapy to RT improves complete pathologic remission up to 38% Xeloda (Capecitabine): oral route 5-FU + Irinotecan/Oxaliplatin + RT Downstaging 67-84% Downstaging 67-84% Biological agents Bevacizumab/Cetuximab Bevacizumab/Cetuximab

Pathologists Quirke’s detailed reporting system for rectal specimen Completeness of mesorectal excision Completeness of mesorectal excision Surgical audit Surgical audit MRI audit MRI audit Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol 2003;4:695–702. Quirke P, Durdey P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996 –9.

Re-staging after neoadjuvant CRT After RT, both EUS and MRI offered poor diagnostic performance in the assessment of T and N stages Mezzi G. et al. Endoscopic ultrasound and magnetic resonance imaging for re- staging rectal cancer after radiotherapy. World J Gastroenterol Nov 28;15(44):

Optimal time for operation 4-6 weeks is optimal Allows RT-induced tissue swelling or local inflammation to subside. Allows RT-induced tissue swelling or local inflammation to subside. Allows time for tumor regression, which may improve resectability and possibility of sphincter preservation. Allows time for tumor regression, which may improve resectability and possibility of sphincter preservation. 1)Lim S-BM et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008; 248:243–251. 2)Veenhof AA et al. Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. Int J Colorectal Dis. 2007;22:507–513

Conclusion For locally advanced rectal cancer: Neoadjuvant ChemoRT Neoadjuvant ChemoRT Accurate pre-op staging Accurate pre-op staging Multidisciplinary team (MDT) approach Multidisciplinary team (MDT) approach

Thank you!